MeRT Receives FDA Clearance as First Nonmedication PTSD Treatment

Fifty-two percent — that is the reported reduction in PTSD symptoms observed in Wave Neuroscience’s FDA-cleared clinical trial for Magnetic e-Resonance Therapy (MeRT). The figure represents more than a four-fold increase in efficacy compared to prior medication-based studies, according to chief medical officer Erik Won, DO.

How MeRT personalizes brain stimulation

MeRT combines electroencephalogram (EEG) mapping with transcranial magnetic stimulation (TMS), using AI-derived multivariate algorithms to tailor treatment protocols to individual brain activity patterns. Unlike traditional TMS — previously cleared by the FDA only for treatment-resistant depression — MeRT adjusts stimulation parameters based on each patient’s unique electrophysiological biomarkers.

“Standard TMS resembles placing a tarp over a leaking roof to manage symptoms,” said Dr. Kenneth S. Ramos, physician scientist at the Texas A&M Health Institute of Biosciences and Technology. “MeRT is intended to be more targeted — like replacing damaged shingles and addressing the source of the problem.”

Ramos, who has spent decades advancing precision medicine, emphasized that human genetic similarity — approximately 99.9% — still leaves room for critical functional variation. MeRT leverages that variation by targeting individual neural signatures associated with PTSD, rather than applying uniform protocols across patients.

Clinical outcomes and comparative efficacy

In the FDA trial, MeRT achieved a 68% remission rate among participants — substantially higher than the maximum 10.9% remission reported in a 2020 review of PTSD medications. Self-reported symptom scores in that earlier review improved by just 6.8 to 10.1 points; MeRT’s trial demonstrated a 52% overall symptom reduction.

“It’s really a quantum change, an inflection point in what we can offer to patients,” Won stated. “From a clinical care perspective, that’s really meaningful.”

Participants underwent five weekly sessions over five to six weeks. Beneficial effects persisted after treatment concluded, according to trial data cited by Wave Neuroscience.

Regulatory pathway and timeline

The MeRT System received FDA breakthrough device designation in 2024 — an accelerated regulatory pathway that reduces administrative delays while maintaining scientific and medical standards. Final FDA clearance followed in under two and a half years, a notably rapid timeline for a medical device clinical trial, which typically requires about a decade.

Dr. Rick Silva, executive director of clinical trials at the Institute of Biosciences and Technology, noted the project began during the COVID-19 pandemic and credited Wave Neuroscience’s team for meeting rigorous regulatory demands. “I’ve been involved in probably close to 1,000 projects in academic medical centers over the years,” Silva said. “When you get to a point where something is going to benefit patients, it’s very professionally gratifying and personally gratifying in many ways as well.”

A new category of PTSD intervention

Dr. Israel Liberzon, distinguished professor in psychiatry and behavioral sciences at the Texas A&M Naresh K. Vashisht College of Medicine and lead psychiatrist on the study, confirmed MeRT is now the only FDA-cleared nonmedication treatment specifically indicated for PTSD.

“Right now, the FDA has approved only two medications for PTSD,” Liberzon said. “Both are SSRIs. This is the first time that in addition to the medication, we have a non-medication option.”

He highlighted limitations of existing alternatives: psychotherapies demand high levels of active participation and often see dropout due to anxiety provocation, while pharmacological treatments carry side-effect burdens and inconsistent outcomes. “People living with PTSD have been left with trial-and-error treatment, medications and their side effects, and limited outcomes—even when treated by the most dedicated and experienced physicians,” Won added.

Broader implications for mental healthcare

Dr. Leslie S. Prichep, chief scientific officer of Wave Neuroscience, traced the MeRT clearance to decades of research into electrical brain activity and personalized intervention strategies. “The FDA clearance of the MeRT System reflects decades of scientific research using electrophysiological biomarkers in identifying abnormal brain activity profiles and guiding personalized intervention strategies,” she said.

Chief executive officer Fred Walke underscored the company’s aim to reduce stigma by aligning mental healthcare with physical medicine standards — using objective imaging to help patients understand the biological basis of their condition. “One of the goals of the company is to create a platform for mental healthcare that uses objective imagery to help patients understand why they’re experiencing life the way that they are,” Walke said.

Wave Neuroscience and Texas A&M Health are collaborating with stakeholders to expand access and secure insurance coverage. “Our hope is that this research and technology can be a catalyst for more widespread development and innovation of more effective, personalized and precision-guided treatments,” Won said. “This is proof positive that population-scale personalized medicine is not just an aspirational goal but is an achievable reality today.”

The MeRT effort unites researchers and clinicians across disciplines to address the burden of PTSD. With FDA clearance secured, the system moves toward broader clinical deployment — particularly relevant given that approximately 17.5 U.S. veterans die by suicide each day, and 7% of veterans receive a new PTSD diagnosis annually.